Research & Clinical Trials
Research & Clinical Trials
Clinical Trials
A clinical trial is a type of research that helps medical professionals learn about benefits and risks associated with promising new treatments or techniques. The ultimate goal of clinical trials is to improve the lives of patients and clinical trials may introduce therapies or technologies before they are available anywhere else.
-
A Phase 2B, Multicenter, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Obefazimod in Subjects with Moderately to Severely Active Crohns Disease +
A Phase 2B, Multicenter, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Obefazimod in Subjects with Moderately to Severely Active Crohns Disease
Protocol No: ABX464-202
Age Group: Adult
Disease Sites: Crohn's Disease
NCT Id: NCT06456593
Phase: II
Principal Investigators: Udayakumar Navaneethan, MD
Eligibility Document -
Attachment Id: 21492
File Name: ABX464-202 Subject Eligibility _Screening Checklist Version 4.1 dated 21Nov2025.docx
URL:
Objective
The primary objective for the Induction Phase is to evaluate the efficacy of obefazimod compared to placebo as induction therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies.
-
Randomized Trial of EUS-Guided Celiac Plexus Block vs. Sham for Palliation of Pain in Chronic Pancreatitis +
Randomized Trial of EUS-Guided Celiac Plexus Block vs. Sham for Palliation of Pain in Chronic Pancreatitis
Protocol No: EPOCH
Age Group: Adult
Disease Sites: Pancreatic Disease
NCT Id: NCT06178315
Phase: N/A
Principal Investigators: Charles Wilcox, MD
Eligibility Document -
Attachment Id: 18972
File Name: EPOCH Version 3.0 20Nov2025 - Subject Eligibility _Screening Checklist.pdf
URL:
Objective
This study is looking at how well a procedure helps relieve pain in people with chronic pancreatitis, by checking if their pain is reduced by half one month after treatment.
-
A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study of Induction and Maintenance Therapy with RO7790121 in Patients with Moderately to Severely Active Crohns Disease. +
A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study of Induction and Maintenance Therapy with RO7790121 in Patients with Moderately to Severely Active Crohns Disease.
Protocol No: GA45331
Age Group: Adult
Disease Sites: Crohn's Disease
NCT Id: NCT06819878
Phase: III
Principal Investigators: Udayakumar Navaneethan, MD
Eligibility Document -
Attachment Id: 19235
File Name: GA45331 Subject Screening Eligibility Checklist Questionnaire Version 2 Date 05May2025UPDATED.docx
URL:
Objective
To evaluate the efficacy of RO7790121 compared with placebo in maintaining response
-
Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial +
Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial
Protocol No: HBOT-UC
Age Group: Adult
Disease Sites: Ulcerative Colitis
NCT Id: NCT05987852
Phase: N/A
Principal Investigators: Udayakumar Navaneethan, MD
Objective
This study is measuring how many patients with rectal bleeding and frequent stools improve by day 5 without needing stronger medications or surgery.
-
A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered with Tirzepatide in Adult Participants with Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight +
A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered with Tirzepatide in Adult Participants with Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight
Protocol No: I6T-MC-AMCD
Age Group: Adult
Disease Sites: Ulcerative Colitis
NCT Id: NCT06937086
Phase: III
Principal Investigators: Udayakumar Navaneethan, MD
Eligibility Document -
Attachment Id: 16960
File Name: I6T-MC-AMCD Subject Eligibility _Screening Checklist Amendment D Dated September 10, 2025.docx
URL:
Objective
To evaluate if concomitant administration of mirikizumab and tirzepatide at the MTD (up to 15 mg) is superior to mirikizumab and placebo in simultaneously achieving clinical remission and weight reduction
-
A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered with Tirzepatide in Adult Participants with Moderately to Severely Active Crohns Disease and Obesity or Overweight +
A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered with Tirzepatide in Adult Participants with Moderately to Severely Active Crohns Disease and Obesity or Overweight
Protocol No: I6T-MC-AMCE
Age Group: Adult
Disease Sites: Crohn's Disease
NCT Id: NCT06937099
Phase: III
Principal Investigators: Udayakumar Navaneethan, MD
Eligibility Document -
Attachment Id: 17016
File Name: I6T-MC-AMCE Subject Eligibility Screening Checklist Amendment version E dated 10Sep2025.docx
URL:
Objective
To evaluate if concomitant administration of mirikizumab and tirzepatide at the MTD (up to 15 mg) is superior to mirikizumab and placebo in simultaneously achieving clinical remission, endoscopic remission, and weight reduction
-
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis +
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
Protocol No: I7P-MC-DSAG
Age Group: Adult
Disease Sites: Ulcerative Colitis
NCT Id: NCT06598943
Phase: II
Principal Investigators: Udayakumar Navaneethan, MD
Eligibility Document -
Attachment Id: 19872
File Name: I7P-MC-DSAG_Amendment a Dated 04-JUN-2024 Subject Eligibility _Screening Checklist.docx
URL:
Objective
To determine whether eltrekibart alone is superior to placebo in inducing clinical remission in participants with moderately to severely active UC
-
Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction Due to Perihilar Cholangiocarcinoma: a Randomized Controlled Trial +
Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction Due to Perihilar Cholangiocarcinoma: a Randomized Controlled Trial
Protocol No: NL76591-029-22
Age Group: Adult
Disease Sites: Biliary Obstruction
NCT Id: NCT05546372
Phase: N/A
Principal Investigators: Ji Bang, MD
Eligibility Document -
Attachment Id: 19432
File Name: RACCOON_Subject Eligibility _Screening Checklist_Version 2.0_01Jan2025.docx
URL:
Objective
The aim is to evaluate whether the use of eRFA prior to uSEMS placement prolongs stent patency in patients with biliary obstruction due to inoperable perihilar cholangocarcinoma.
-
Paclitaxel Coated Balloon for the Treatment of Chronic Benign Stricture- Bowel +
Paclitaxel Coated Balloon for the Treatment of Chronic Benign Stricture- Bowel
Protocol No: PATENT-B
Age Group: Adult
Disease Sites: Bowel Stricture
NCT Id: NCT05561127
Phase: N/A
Principal Investigators: Udayakumar Navaneethan, MD
Eligibility Document -
Attachment Id: 20555
File Name: Subject Eligibility _Screening Checklist_PATENT-B Version D .docx
URL:
Objective
This study is checking how well the treatment opens up the esophagus without needing another procedure within 6 months, and how often serious side effects like bleeding or injury happen within 30 days.
-
A Phase 2A, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 Administered by Endoscopic Ultrasound-Guided Peripancreatic Injection Plus Standard-of-Care Versus Standard-of-Care Only in Participants with Predicted Severe Acute Pancreatitis +
A Phase 2A, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 Administered by Endoscopic Ultrasound-Guided Peripancreatic Injection Plus Standard-of-Care Versus Standard-of-Care Only in Participants with Predicted Severe Acute Pancreatitis
Protocol No: RABI-767-201
Age Group: Adult
Disease Sites: Pancreatitis
NCT Id: NCT06080789
Phase: II
Principal Investigators: Charles Wilcox, MD
Eligibility Document -
Attachment Id: 16812
File Name: RABI-767-201 Version 3.1 23Sep2024 - Subject Eligibility _Screening Checklist.pdf
URL:
Objective
To evaluate the safety of a single dose of RABI-767 administered by EUS-guided peripancreatic injection plus standard-of-care versus standard-of-care only in adult participants with predicted severe acute pancreatitis.
-
Randomized Trial of Rectal Indomethacin to Prevent Acute Pancreatitis in Patients Undergoing Endoscopic Ultrasound-guided Fine Needle Aspiration of Pancreatic Cysts +
Randomized Trial of Rectal Indomethacin to Prevent Acute Pancreatitis in Patients Undergoing Endoscopic Ultrasound-guided Fine Needle Aspiration of Pancreatic Cysts
Protocol No: RECTAL-INDO-PAN-CYSTS
Age Group: Adult
Disease Sites: Pancreatic Disease
NCT Id: NCT05572788
Phase: N/A
Principal Investigators: Ji Bang, MD
Eligibility Document -
Attachment Id: 16412
File Name: IndoPanCysts Version 22Dec2022 - Subject Eligibility _Screening Checklist.pdf
URL:
Objective
The primary outcome measure is to compare the rate of post-procedure pancreatitis following EUS-guided fine needle aspiration of pancreatic cysts between the indomethacin group and placebo group.
-
A Randomized, Double-blind, Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab and Oral Placebo for Induction Followed by Intravenous Vedolizumab Monotherapy for Maintenance in the Treatment of Adults With Moderately to Severely Active Crohn's Disease +
A Randomized, Double-blind, Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab and Oral Placebo for Induction Followed by Intravenous Vedolizumab Monotherapy for Maintenance in the Treatment of Adults With Moderately to Severely Active Crohn's Disease
Protocol No: VEDOLIZUMAB-3043
Age Group: Adult
Disease Sites: Crohn's Disease
NCT Id: NCT06227910
Phase: III
Principal Investigators: Udayakumar Navaneethan, MD
Eligibility Document -
Attachment Id: 13663
File Name: Vedolizumab-3043 version 4 01may2025 - Subject Eligibility _Screening Checklist.pdf
URL:
Objective
This study is checking how many people with Crohns disease feel better and show healing in their intestines after 12 weeks of treatment, based on symptom scores and results from a scope exam.
New treatments follow strict guidelines and must be approved by the U.S. Food and Drug Administration (FDA) before they are made available for standard use. Clinical trials are a key part of that process.
Contact Us
If you would like more information on a specific clinical trial, please reach out to BJ Broome, MBAHM, Senior Director, Research and Clinical Trial Operations at (321) 841–4356
ER Wait Times
Information will update every 5 minutes. ER Wait Times are approximate and provided for informational purposes only. Estimated Wait Times as of: Wednesday, February 25, 2026 9:23 PM
|
|
Wait Time | |
|---|---|---|
| Orlando Health - Health Central Hospital | Directions | 9 min |
| Orlando Health Arnold Palmer Hospital for Children | Directions | 90 min |
| Orlando Health Bayfront Hospital Emergency Room | Directions | 119 min |
| Orlando Health Dr. P. Phillips Hospital | Directions | 9 min |
| Orlando Health Emergency Room - Blue Cedar | Directions | 1 min |
| Orlando Health Emergency Room - Crossroads | Directions | 1 min |
| Orlando Health Emergency Room - Four Corners | Directions | 6 min |
| Orlando Health Emergency Room - Lake Mary | Directions | 26 min |
| Orlando Health Emergency Room - Longwood | Directions | 4 min |
| Orlando Health Emergency Room - Osceola | Directions | 27 min |
| Orlando Health Emergency Room - Pinellas Park | Directions | 9 min |
| Orlando Health Emergency Room - Randal Park | Directions | 29 min |
| Orlando Health Emergency Room - Reunion Village | Directions | 12 min |
| Orlando Health Emergency Room - Waterford Lakes | Directions | 15 min |
| Orlando Health Horizon West Hospital | Directions | 12 min |
| Orlando Health Melbourne Hospital | Directions | 52 min |
| Orlando Health Orlando Regional Medical Center | Directions | 99 min |
| Orlando Health Sebastian River Hospital | Directions | 6 min |
| Orlando Health South Lake Hospital | Directions | 203 min |
| Orlando Health St. Cloud Hospital | Directions | 74 min |